Skip to Content


Active Substance: efalizumab
Common Name: efalizumab
ATC Code: L04AA21
Marketing Authorisation Holder: Serono Europe Limited
Active Substance: efalizumab
Status: Withdrawn
Authorisation Date: 2004-09-20
Therapeutic Area: Psoriasis
Pharmacotherapeutic Group: Immunosuppressants

Therapeutic Indication

Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).

The marketing authorisation for Raptiva has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.